AI-assisted, human-published
07/01/2026 /Funding Events
Ollin Biosciences Raises $330 Million in Series B Financing for Vision-Threatening Disease Therapies
Ollin Biosciences secures oversubscribed Series B financing to advance best-in-disease therapies for vision-threatening diseases with co-leaders TCGX and ARCH Venture Partners and participation from prominent healthcare-focused crossover investors.
AI-assisted, human-published
Latest headlines
-
-
-
Stay connected!
If you have a serious, bonafide inquiry into the VentureCapital.com or PrivateEquity.com domain names, please contact us here
©2023 VentureCapital.com